{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "DKK", "esgPopulated": false, "market": "gb_market", "longName": "Genmab A/S", "marketState": "CLOSED", "regularMarketPrice": 2872.0, "exchange": "IOB", "shortName": "GENMAB A/S GENMAB ORD SHS", "exchangeTimezoneShortName": "BST", "exchangeTimezoneName": "Europe/London", "regularMarketChangePercent": -0.45060658, "gmtOffSetMilliseconds": 3600000, "fiftyTwoWeekLowChange": 1008.0, "fiftyTwoWeekLowChangePercent": 0.54077256, "fiftyTwoWeekRange": "1864.0 - 3325.0", "fiftyTwoWeekHighChange": -453.0, "fiftyTwoWeekHighChangePercent": -0.1362406, "fiftyTwoWeekLow": 1864.0, "fiftyTwoWeekHigh": 3325.0, "trailingAnnualDividendRate": 0.0, "trailingPE": 34.60658, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": 82.99, "firstTradeDateMilliseconds": 1306479600000, "priceHint": 2, "regularMarketChange": -13.0, "regularMarketTime": 1683913508, "regularMarketDayHigh": 2877.0, "regularMarketDayRange": "2810.0 - 2877.0", "regularMarketDayLow": 2810.0, "regularMarketVolume": 32051, "regularMarketPreviousClose": 2885.0, "bid": 2744.0, "ask": 2930.0, "bidSize": 0, "askSize": 0, "fullExchangeName": "IOB", "financialCurrency": "DKK", "regularMarketOpen": 2813.0, "averageDailyVolume3Month": 26194, "averageDailyVolume10Day": 12452, "sharesOutstanding": 65222500, "bookValue": 419.769, "fiftyDayAverage": 2646.58, "fiftyDayAverageChange": 225.41992, "fiftyDayAverageChangePercent": 0.08517404, "twoHundredDayAverage": 2775.4624, "twoHundredDayAverageChange": 96.5376, "twoHundredDayAverageChangePercent": 0.03478253, "marketCap": 187319025664, "priceToBook": 6.841858, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "symbol": "0MGB.IL"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Kalvebod Brygge 43", "city": "Copenhagen", "zip": "1560", "country": "Denmark", "phone": "45 70 20 27 28", "website": "https://www.genmab.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.", "fullTimeEmployees": 1660, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jan G.J. van de Winkel Ph.D.", "age": 61, "title": "Co-Founder, Pres & CEO", "yearBorn": 1961, "fiscalYear": 2022, "totalPay": {"raw": 18800000, "fmt": "18.8M", "longFmt": "18,800,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Anthony  Pagano", "age": 44, "title": "Exec. VP & CFO", "yearBorn": 1978, "fiscalYear": 2022, "totalPay": {"raw": 7000000, "fmt": "7M", "longFmt": "7,000,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Anthony  Mancini", "age": 51, "title": "Exec. VP & COO", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": {"raw": 7600000, "fmt": "7.6M", "longFmt": "7,600,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Martin  Schultz", "age": 46, "title": "Sr. Director of Clinical Operations  & Non-Independent Director", "yearBorn": 1976, "fiscalYear": 2022, "totalPay": {"raw": 500000, "fmt": "500k", "longFmt": "500,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Judith V. Klimovsky M.D.", "age": 64, "title": "Exec. VP & Chief Devel. Officer", "yearBorn": 1958, "fiscalYear": 2022, "totalPay": {"raw": 7900000, "fmt": "7.9M", "longFmt": "7,900,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Tahamtan  Ahmadi", "age": 49, "title": "Exec. VP, Chief Medical Officer & Head of Experimental Medicines", "yearBorn": 1973, "fiscalYear": 2022, "totalPay": {"raw": 7500000, "fmt": "7.5M", "longFmt": "7,500,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Mijke  Zachariasse Ph.D.", "age": 48, "title": "Sr. Director, Head of Antibody Research Materials & Non-Independent Director", "yearBorn": 1974, "fiscalYear": 2022, "totalPay": {"raw": 1000000, "fmt": "1M", "longFmt": "1,000,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Takahiro  Hamatani", "age": 47, "title": "Sr. Director of Fin. Japan & Non-Independent Director", "yearBorn": 1975, "fiscalYear": 2022, "totalPay": {"raw": 500000, "fmt": "500k", "longFmt": "500,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Andrew  Carlsen", "title": "Sr. Director, VP & Head of Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Birgitte  Stephensen M.Sc.", "age": 61, "title": "Exec. VP & Chief Legal Officer", "yearBorn": 1961, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 2, "boardRisk": 1, "compensationRisk": 3, "shareHolderRightsRisk": 1, "overallRisk": 1, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}